Irinotecan/Capecitabine Versus Capecitabine in Patients Treated With A/T for HER2 Negative Metastatic Breast Cancer

PHASE3UnknownINTERVENTIONAL
Enrollment

222

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

February 28, 2014

Study Completion Date

February 28, 2014

Conditions
Metastatic Breast Cancer
Interventions
DRUG

Irinotecan, Capecitabine

"Irinotecan 80 mg/m2, day 1 and 8, every 3 weeks~\+ capecitabine 1000 mg/m2, BID, day 1-14, every 3 weeks"

Trial Locations (1)

Unknown

RECRUITING

National Cancer Center, Goyang-si

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Asan Medical Center

OTHER

collaborator

Chung-Ang University

OTHER

collaborator

Inha University Hospital

OTHER

collaborator

Korea University Anam Hospital

OTHER

collaborator

Samsung Medical Center

OTHER

collaborator

Severance Hospital

OTHER

collaborator

Seoul National University Hospital

OTHER

collaborator

Seoul National University Bundang Hospital

OTHER

lead

National Cancer Center, Korea

OTHER_GOV